Galectin Net Debt To E B I T D A from 2010 to 2024
| GALT Stock | USD 2.89 0.05 1.76% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter (228.45) | Current Value (217.03) | Quarterly Volatility 78.74258196 |
Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 40 M, Interest Expense of 2.7 M or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0016 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.
Galectin | Net Debt To E B I T D A |
Latest Galectin Therapeutics' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Galectin Therapeutics over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Galectin Therapeutics' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galectin Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Galectin Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | (28.88) | |
| Coefficient Of Variation | (272.67) | |
| Mean Deviation | 51.70 | |
| Median | 0.68 | |
| Standard Deviation | 78.74 | |
| Sample Variance | 6,200 | |
| Range | 232 | |
| R-Value | (0.59) | |
| Mean Square Error | 4,358 | |
| R-Squared | 0.35 | |
| Significance | 0.02 | |
| Slope | (10.38) | |
| Total Sum of Squares | 86,806 |
Galectin Net Debt To E B I T D A History
About Galectin Therapeutics Financial Statements
Galectin Therapeutics shareholders use historical fundamental indicators, such as Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Galectin Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Galectin Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | (228.45) | (217.03) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.